Covered recipient · General Payments record
HENRIK BO ILLUM
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$218.19
5 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $199.90 | 2 |
| Food and Beverage | $18.29 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Seattle Genetics, Inc. | $118.24 | 4 |
| Incyte Corporation | $99.95 | 1 |
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HENRIK BO ILLUM
NPI 1982805164 · CMS profile ID 818448
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BEDFORD, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1982805164?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982805164?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982805164?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982805164?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
5 matching records · $218.19 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–5 of 5.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Seattle Genetics, Inc. | $4.53 | 11/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678807561 | CMS |
| Seattle Genetics, Inc. | $99.95 | 11/06/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678807563 | CMS |
| Seattle Genetics, Inc. | $5.00 | 09/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678807559 | CMS |
| Seattle Genetics, Inc. | $8.76 | 06/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678807555 | CMS |
| Incyte Corporation | $99.95 | 01/31/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666273897 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $30,785.70 | 23 |
| PY2024 | Principal investigator | $56,382.74 | 49 |
| PY2023 | Principal investigator | $148,965.97 | 74 |
| PY2022 | Principal investigator | $217,097.35 | 91 |
| PY2021 | Principal investigator | $222,524.42 | 113 |
| PY2020 | Principal investigator | $248,821.20 | 67 |
| PY2019 | Recipient | $1,250.00 | 1 |
| PY2019 | Principal investigator | $428,314.17 | 79 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
80 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Amgen Inc. | $6,678.00 | 12/24/2019 | Non-covered Recipient Entity US ONC RESEARCH LLC | Prospective Observational Study of Onpro vs SOC | No dispute reported | 06/30/2026 | 675778773 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 12/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510067 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,206.00 | 12/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822169 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 11/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510069 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 11/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510071 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,620.00 | 11/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822157 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,281.00 | 11/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822159 |
| Principal investigator 1 | Seattle Genetics, Inc. | $275.00 | 11/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822167 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,281.00 | 11/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822177 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,060.00 | 11/05/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639761533 |
| Principal investigator 1 | EMD Serono, Inc. | $750.00 | 10/15/2019 | Non-covered Recipient Entity Texas Oncology, Pa | MS200647-0037 | No dispute reported | 06/30/2026 | 703033145 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 10/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510063 |
| Principal investigator 1 | Eisai Inc. | $1,088.00 | 10/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510065 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 10/15/2019 | Non-covered Recipient Entity Ghs Greenville Memorial Hospital | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673102385 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 10/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673102547 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 10/15/2019 | Non-covered Recipient Entity Ghs Greenville Memorial Hospital | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673102643 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 10/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673102659 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 09/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510055 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 09/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510057 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 09/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510061 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $120.00 | 08/15/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639761529 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 08/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510059 |
| Principal investigator 1 | Seattle Genetics, Inc. | $275.00 | 08/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822151 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510035 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510037 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510039 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510041 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510043 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510045 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510047 |
| Principal investigator 1 | Eisai Inc. | $1,020.00 | 07/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510051 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 07/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673101653 |
| Principal investigator 1 | Seattle Genetics, Inc. | $182.00 | 07/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822129 |
| Principal investigator 1 | Seattle Genetics, Inc. | $275.00 | 07/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822145 |
| Principal investigator 1 | Seattle Genetics, Inc. | $182.00 | 07/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822147 |
| Principal investigator 1 | Seattle Genetics, Inc. | $182.00 | 07/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822149 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,250.00 | 07/12/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639761527 |
| Principal investigator 1 | Eisai Inc. | $1,088.00 | 06/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510049 |
| Principal investigator 1 | EMD Serono, Inc. | $7,650.00 | 05/15/2019 | Non-covered Recipient Entity Texas Oncology, Pa | MS 200647-0037 | No dispute reported | 06/30/2026 | 703036221 |
| Principal investigator 1 | Eisai Inc. | $175.00 | 05/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510053 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,020.00 | 05/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822075 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,720.00 | 05/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822077 |
| Principal investigator 1 | Seattle Genetics, Inc. | $847.00 | 05/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822079 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,020.00 | 05/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822107 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,020.00 | 05/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822109 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,468.00 | 05/01/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639761531 |
| Principal investigator 1 | Acerta Pharma LLC | $3,750.00 | 04/23/2019 | Non-covered Recipient Entity Us Oncology Research | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 685002775 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 04/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673099165 |
| Principal investigator 1 | Seattle Genetics, Inc. | $175.00 | 04/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822057 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,435.00 | 04/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822059 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $64,802.00 | 03/15/2019 | Non-covered Recipient Entity Texas Oncology | Phase IIIII 1L CRC NivoCT wpt segmentationrational combos | No dispute reported | 06/30/2026 | 639761543 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 03/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673093709 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,161.00 | 03/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822051 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,161.00 | 03/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822097 |
| Principal investigator 1 | Amgen Inc. | $72,578.00 | 02/26/2019 | Non-covered Recipient Entity US ONC RESEARCH LLC | Prospective Observational Study of Onpro vs SOC | No dispute reported | 06/30/2026 | 675795886 |
| Principal investigator 1 | Amgen Inc. | $48,715.00 | 02/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | Prospective Observational Study of Onpro vs SOC | No dispute reported | 06/30/2026 | 675793817 |
| Principal investigator 1 | Celgene Corporation | $3,570.00 | 02/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | Celgene - Connect MM | No dispute reported | 06/30/2026 | 675419105 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,161.00 | 02/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822047 |
| Principal investigator 1 | Seattle Genetics, Inc. | $275.00 | 02/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822049 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $19,531.00 | 02/01/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639761535 |
| Recipient | Acerta Pharma LLC | $1,250.00 | 01/25/2019 | Covered Recipient Physician | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 685006165 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,550.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 639754817 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,146.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | SUSTAIN, event driven trial | No dispute reported | 06/30/2026 | 639761537 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,868.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway | No dispute reported | 06/30/2026 | 639761539 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,163.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | Phase III 1L Gastric combo vs nivo CT | No dispute reported | 06/30/2026 | 639761541 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,426.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices | No dispute reported | 06/30/2026 | 639761545 |
| Principal investigator 1 | Eisai Inc. | $300.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510031 |
| Principal investigator 1 | Eisai Inc. | $1,481.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510033 |
| Principal investigator 1 | Eisai Inc. | $1,358.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, PA SOUTHWEST FORT WORTH CANCER CENTER | A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | No dispute reported | 06/30/2026 | 702510073 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $516.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY PA SOUTHWEST FT WORTH | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO RECEIVED NO PRIOR HORMONAL THERAPY FOR ADVANCED DI | No dispute reported | 06/30/2026 | 640727873 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673093413 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,020.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822039 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,435.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822041 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,720.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822043 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,020.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822091 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,020.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822093 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,020.00 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY - BEDFORD | A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma HL in Adults Age 60 and Above | No dispute reported | 06/30/2026 | 678822095 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,569.00 | 01/09/2019 | Non-covered Recipient Entity Us Oncology Res Llc | Phase III 1L Gastric nivo ipi vs nivo CT vs CT | No dispute reported | 06/30/2026 | 639761549 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $85,330.65 | 01/04/2019 | Non-covered Recipient Entity Us Oncology Res Llc | Phase II III 1L CRC Nivo CT w pt segmentation rational combos | No dispute reported | 06/30/2026 | 708963945 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,961.52 | 01/01/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY BEDFORD | TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING | No dispute reported | 06/30/2026 | 640727807 |